Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 1/2 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 39UNKNOWN 5INDUSTRY 2OTHER_GOV 1

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Tumor-Agnostic 1Other solid neoplasm 1

Conditions

Carcinoma, Squamous Cell 1Advanced Solid Tumor 1

Interventions

pembrolizumab 1019Carboplatin 959Paclitaxel 932Gemcitabine 793Cisplatin 748Docetaxel 682Bevacizumab 610Pemetrexed 502Nivolumab 486Cyclophosphamide 466Capecitabine 461Fluorouracil 417Dexamethasone 402Rituximab 372Oxaliplatin 347Injections 342atezolizumab 297Trastuzumab 297Leucovorin 286Cetuximab 282Irinotecan 266130-nm albumin-bound paclitaxel 252Prednisone 244Doxorubicin 240Ipilimumab 226Lenalidomide 220Fulvestrant 217fludarabine 214durvalumab 205Erlotinib Hydrochloride 188

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Interventional × nedaplatin × Clear all
NCT06953323 2026-03-27

A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid Tumors

Wigen Biomedicine Technology (Shanghai) Co., Ltd.

Phase 1/2 Recruiting
86 enrolled
Other solid neoplasm

Advanced Solid Tumor

NCT02088515 2017-03-03

Nedaplatin (Jiebaishu®) Combined With Docetaxel for Advanced Lung Squamous Cell Carcinoma

Jiangsu Simcere Pharmaceutical Co., Ltd.

Phase 4 Completed
290 enrolled
Tumor-Agnostic

Carcinoma, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡